Ken Griffin Solid Biosciences Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.43 - $1.24 $25,748 - $74,251	59,880 Added 577.88%	70,242 $44,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.79 $43,362 - $104,890	-58,598 Reduced 84.97%	10,362 $12,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $82,123 - $119,541	48,594 Added 238.6%	68,960 $120,000
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $38,974 - $61,737	-16,376 Reduced 44.57%	20,366 $49,000
Q2 2021 Aug 16, 2021	SELL	$3.49 - $5.51 $8.61 Million - $13.6 Million	-2,467,020 Reduced 98.53%	36,742 $134,000
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $13.3 Million - $26.6 Million	2,477,646 Added 9487.08%	2,503,762 $13.8 Million
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $26,694 - $67,515	8,667 Added 49.67%	26,116 $198,000
Q3 2020 Nov 16, 2020	SELL	$2.02 - $3.08 $212,473 - $323,969	-105,185 Reduced 85.77%	17,449 $35,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $3.42 $88,987 - $144,922	42,375 Added 52.8%	122,634 $359,000
Q1 2020 May 15, 2020	SELL	$2.31 - $4.43 $275,391 - $528,131	-119,217 Reduced 59.77%	80,259 $192,000
Q4 2019 Feb 14, 2020	SELL	$2.82 - $12.9 $467,149 - $2.14 Million	-165,656 Reduced 45.37%	199,476 $888,000
Q3 2019 Nov 14, 2019	BUY	$4.33 - $11.64 $751,306 - $2.02 Million	173,512 Added 90.55%	365,132 $3.78 Million
Q2 2019 Aug 14, 2019	SELL	$4.6 - $10.13 $1.51 Million - $3.33 Million	-328,766 Reduced 63.18%	191,620 $1.1 Million
Q1 2019 May 15, 2019	BUY	$7.19 - $32.37 $3.52 Million - $15.8 Million	488,914 Added 1553.49%	520,386 $0
Q1 2018 May 11, 2018	BUY	$7.19 - $33.17 $226,283 - $1.04 Million	31,472 New	31,472 $236,000

Others Institutions Holding SLDB

# of Institutions

Shares Held

Call Options Held

Put Options Held

View Full List

About Solid Biosciences Inc.

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

More about SLDB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account